RT Journal
A1 Papadakis JA, Mikhailidis DP
T1 Coronary events with lipid-lowering therapy: The afcaps/texcaps trial
JF JAMA
JO JAMA
YR 1999
FD February 3
VO 281
IS 5
SP 414
OP 419
DO 10-1001/pubs.JAMA-ISSN-0098-7484-281-5-jbk0203
UL http://dx.doi.org/10-1001/pubs.JAMA-ISSN-0098-7484-281-5-jbk0203
AB 
To the Editor: The results of
AFCAPS/TexCAPS1 are impressive in terms of primary vascular
disease prevention. The significant (P=.04)
reduction in melanoma cases (14 vs 27) in the lovastatin group is also
of interest because this drug inhibits melanoma cell growth in animal
models.2- 4 The mechanism involved is not clearly defined.
We could not identify any publications involving other statins in
similar models of melanoma. However, statins (eg, simvastatin) have
been suggested to potentiate the effect of antiblastic drugs on tumor
growth.5